BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
177 results:

  • 1. Effective delivery of anti-pd-l1 siRNA with human heavy chain ferritin (HFn) in acute myeloid leukemia cell lines.
    Rajabinejad M; Valadan R; Tehrani M; Najafi A; Negarandeh R; Saeedi M; Asgarian-Omran H
    Med Oncol; 2024 May; 41(6):149. PubMed ID: 38739199
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
    Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells.
    Camoglio C; Balla J; Fadda P; Dedoni S
    Molecules; 2024 Apr; 29(7):. PubMed ID: 38611871
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.
    Saigí M; Mate JL; Carcereny E; Martínez-Cardús A; Esteve A; Andreo F; Centeno C; Cucurull M; Mesia R; Pros E; Sanchez-Cespedes M
    Lung Cancer; 2024 Mar; 189():107502. PubMed ID: 38359742
    [TBL] [Abstract] [Full Text] [Related]  

  • 5.
    Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Clinicopathological Study of PD-1/pd-l1 Expression in Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.
    Masoud R; Eladl AE; El-Ashwah S; Abbas A; Kandil W
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4243-4252. PubMed ID: 38156860
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Whole-genome CRISPR screening identifies molecular mechanisms of pd-l1 expression in adult T-cell leukemia/lymphoma.
    Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
    Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. PD-1/pd-l1 Interaction Regulates BCL2, KI67, BAX, and CASP3, Altering Proliferation, Survival, and Apoptosis in Acute Myeloid leukemia.
    Soltani M; Vosoughi M; Ganjalikhani-Hakemi M; Shapoorian H; Beshkar P; Eskandari N; Ghezelbash B
    Iran J Allergy Asthma Immunol; 2023 Oct; 22(5):495-503. PubMed ID: 38085150
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Development of PD-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia.
    Wang Q; Huang H; Liang P; Wang L; Zheng J; Zhang Y; Wang H
    Med Oncol; 2023 Dec; 41(1):14. PubMed ID: 38078948
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Identification and validation of necroptosis-related gene signatures to predict clinical outcomes and therapeutic responses in acute myeloid leukemia.
    Wen XM; Xu ZJ; Ma JC; Xia PH; Jin Y; Chen XY; Qian W; Lin J; Qian J
    Aging (Albany NY); 2023 Nov; 15(24):14677-14702. PubMed ID: 37993258
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Combination therapy of acute myeloid leukemia by dual PI3K/mTOR inhibitor BEZ235 and TLR-7/8 agonist R848 in murine model.
    Taghiloo S; Ajami A; Alizadeh-Navaei R; Asgarian-Omran H
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111211. PubMed ID: 37956488
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Combined or Sequential treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review.
    Pérez-Moreno MA; Ciudad-Gutiérrez P; Jaramillo-Ruiz D; Reguera-Ortega JL; Abdel-Kader Martín L; Flores-Moreno S
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834228
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Progress of research on PD-1/pd-l1 in leukemia.
    Cao H; Wu T; Zhou X; Xie S; Sun H; Sun Y; Li Y
    Front Immunol; 2023; 14():1265299. PubMed ID: 37822924
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. THE ROLE GENE EXPRESSION OF PD-1 AND pd-l1 IN NEWELY DIAGNOSED AND TREATED PATIENTS WITH ACUTE MYELOID leukemia.
    Al-Saedi S; Hamzah I
    Georgian Med News; 2023; (340-341):25-29. PubMed ID: 37805869
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. STAT5 promotes pd-l1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia.
    Huang ZW; Zhang XN; Zhang L; Liu LL; Zhang JW; Sun YX; Xu JQ; Liu Q; Long ZJ
    Signal Transduct Target Ther; 2023 Sep; 8(1):391. PubMed ID: 37777506
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
    Cai L; Li Y; Tan J; Xu L; Li Y
    J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Exosomal circRNA-001264 promotes AML immunosuppression through induction of M2-like macrophages and pd-l1 overexpression.
    Du A; Yang Q; Sun X; Zhao Q
    Int Immunopharmacol; 2023 Nov; 124(Pt A):110868. PubMed ID: 37657244
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Circ_0001946 Promotes the Development of Acute Myeloid leukemia by Upregulating pdl1.
    Li G; Zhu C; Qiao D; Chen R
    Turk J Haematol; 2023 Aug; 40(3):154-161. PubMed ID: 37431262
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. AKT inhibition interferes with the expression of immune checkpoint proteins and increases NK-induced killing of HL60-AML cells.
    Gama SM; Varela VA; Ribeiro NM; Bizzarro B; Hernandes C; Aloia TPA; Amano MT; Pereira WO
    Einstein (Sao Paulo); 2023; 21():eAO0171. PubMed ID: 37341216
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Association of CDKN2A/B mutations, PD-1, and pd-l1 with the risk of acute lymphoblastic leukemia in children.
    Ruan Y; Xie L; Zou A
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10841-10850. PubMed ID: 37314514
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 9.